Program
sodium phosphate
Also written as “Sodium Phosphates Injection”, “Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)” and “Oral sodium phosphate solution”.
Its studies are led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratoires Mayoly Spindler | 20 open or running | phase 3since Apr 23, 2013 | Jul 13, 2011 | none ahead |
| Bausch Health Companies | 10 open or running | phase 4since Aug 30, 2011 | Aug 30, 2011 | none ahead |
| Baxter Healthcare | 10 open or running | phase 1since Feb 11, 2025 | Feb 11, 2025 | none ahead |
| Universal Integrated | 10 open or running | phase 3since Jun 6, 2019 | Jun 6, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2011First study: phase 2 study in ColonoscopyNew to Laboratoires Mayoly SpindlerLaboratoires Mayoly Spindler · NCT01398098 · 30 enrolled · France
- Aug 30, 2011Bausch Health Companies's first study: phase 4 study in Colon CleansingNew to Bausch Health CompaniesBausch Health Companies · NCT01427296 · 2,154 enrolled · United States
- Apr 23, 2013Phase 3 study in Colon CleansingLaboratoires Mayoly Spindler · NCT01840553 · 461 enrolled · France, Germany, Spain
- Jun 6, 2019Universal Integrated's first study: phase 3 study in Bowel PreparationNew to Universal IntegratedUniversal Integrated · NCT03992365 · 472 enrolled · Taiwan
- Feb 11, 2025Baxter Healthcare's first study: phase 1 study in HyperphagiaNew to Baxter HealthcareBaxter Healthcare · NCT06842121 · 42 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06842121Hyperphagia · United States | 1 | Completed | Baxter Healthcare | May 22, 2025 | 42 |
| NCT03992365Bowel Preparation · Taiwan | 3 | Completed | Universal Integrated | Oct 15, 2019 | 472 |
| NCT01840553Colon Cleansing · France, Germany, Spain | 3 | Completed | Laboratoires Mayoly Spindler | Mar 2014 | 461 |
| NCT01427296Colon Cleansing · United States | 4 | Completed | Bausch Health Companies | Mar 11, 2014 | 2,154 |
| NCT01398098Colonoscopy · France | 2 | Completed | Laboratoires Mayoly Spindler | May 2012 | 30 |
How it is read
Names in the registry
- “Sodium Phosphates Injection”, 1 entry
- “Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)”, 1 entry
- “Oral sodium phosphate solution”, 1 entry
- “oral sodium phosphate tablets”, 1 entry
- “Sodium phosphate”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.